Genetic Chronic Obstructive Pulmonary Disease Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023

Description

Alpha-1 deficiency-related emphysema is called as genetic Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic illness, and some of its symptoms include wheezing, mucus production, and breathing difficulties. Chronic bronchitis, emphysema, and refractory asthma are all symptoms of COPD, a degenerative lung condition. Chronic obstructive pulmonary disease (COPD) is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors.

Each year, millions of people are affected by chronic obstructive pulmonary disease, or COPD for short. Emphysema and chronic bronchitis are two conditions that are collectively referred to as COPD. The lungs' alveoli, which are air sacs, suffer damage in emphysema. Breathlessness while exercising is the first sign of emphysema. Later, breathing difficulties can also happen while at rest. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing.

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product launch and approval is expected to drive market growth over the forecast period. For instance, in September 2020, GSK, Plc.,a pharmaceutical company and Innoviva Inc., a healthcare focused asset management company, announced that the U.S. Food and Drug Administration (FDA) approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the treatment of asthma in patients 18 years and older, expanding the current approval for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. Moreover, several prospective drugs, primarily for COPD, are in the pipeline for respiratory illnesses, which is anticipated to boost growth of the global genetic chornic obstructive pulmonary disease (COPD) market.

Key features of the study:

This report provides an in-depth analysis of the global genetic chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (us$ million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
it profiles key players in the global genetic chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study GSK Plc., AstraZeneca Plc., Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global genetic chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genetic chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
- Bronchodilators
- Phosphodiesterase Type 4 Inhibitors
- Steroids
- Antibiotics
- Others
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
- Oral
- Nasal
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- GSK Plc*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca Plc
- Merck (Sigma-Aldrich)
- Dey Pharma
- Grifols, S.A.
- Teva Pharmaceutical Industries Ltd
- Baxter
- Boehringer Ingelheim International GmbH
- Kamada Ltd
- Takeda Pharmaceutical Company Limited.
- LFB SA
- Abeona Therapeutics
- Alnylam Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
- Kedrion S.p.A.
- Arrowhead Pharmaceuticals, Inc

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI5512

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Key Highlights
Research and Development Collaboration, Mergers, and Acquisitions
PEST Analysis
Pipeline Analysis
Epidemiology

4. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market - Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Steroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Route Of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Nasal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Heat Map Analysis
Company Profiles
- GSK Plc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- AstraZeneca Plc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Merck (Sigma-Aldrich)
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Dey Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Grifols, S.A.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Teva Pharmaceutical Industries Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Baxter
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Boehringer Ingelheim International GmbH
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Kamada Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Takeda Pharmaceutical Company Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- LFB SA
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Abeona Therapeutics
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Alnylam Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Vertex Pharmaceuticals Incorporated
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Kedrion S.p.A.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Arrowhead Pharmaceuticals, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies

10. Section

References
Research Methodology
About Us and Sales Contact

Genetic Chronic Obstructive Pulmonary Disease Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030